Lercanidipine
Therapeutic Category
- Anti-hypertensive
Innovator Brand
GMP
DMF
Filed
Under Filing
Sample
Indication
Lercanidipine HCl is indicated in adults for the treatment of mild to moderate essential hypertension. The recommended dosage is 10 mg orally once a day at least 15 minutes before meals; the dose may be increased to 20 mg depending on the individual patient’s response.
CTX Lifesciences, is one of the leading Active Pharmaceutical Ingredients ( API ) manufacturer and supplier globally for Lercanidipine with CAS Number: 100427-26-7. We are a leading exporter of Lercanidipine with CAS Number: 100427-26-7. We are a trusted supplier with API exports in more than 87 Countries including the US, Europe, Brazil, Latin America, China, Korea, Middle East and other emerging markets.
CTX also offers other Angiotensin II Receptor Blocker (arb) as mentioned below. Please check them out below.
Azilsartan Medoxomil Potassium
CTX Lifesciences also offers series of Diuretic as mentioned below within the hypertensive segment .
CTX also offers other β1 receptor blocker API as mentioned below. Please check them out below.
CTX also offers other Angiotensin II Receptor Blocker (arb) as mentioned below. Please check them out below.
Azilsartan Medoxomil Potassium
CTX Lifesciences also offers series of Diuretic as mentioned below within the hypertensive segment .
CTX also offers other β1 receptor blocker API as mentioned below. Please check them out below.
CTX Lifesciences is one of the leading API manufacturer & supplier of Lercanidipine with CAS Number: 100427-26-7. This product is provided from our GMP compliant plant with product made under complete cGMP conditions. We provided with documentation support Drug Master File ( DMF ). Our manufacturing plant at Surat has accreditation by US-FDA, EDQM, EMA, ANVISA, KFDA, Health Canada & Russian Authorities.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.